

Conjugate Vaccines Market 2026

<https://marketpublishers.com/r/C93932A0DE91EN.html>

Date: February 2026

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: C93932A0DE91EN

Abstracts

The Conjugate Vaccines Market was valued at in and is anticipated to reach by , at a CAGR of 0.095 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Conjugate Vaccines Market.

This report delivers a comprehensive overview of the Conjugate Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Conjugate Vaccines Market. The Conjugate Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Conjugate Vaccines Market Scope:

By Product Type

Monovalent Conjugate Vaccines

Multivalent Conjugate Vaccine

By Disease Indication

Pneumococcal

Influenza

Meningococcal

Others

By Pathogen Type

Bacterial

Viral

By Patient Type

Pediatric

Adults

Key Players

GlaxoSmithKline plc.

Merck & Co. Inc.

Fablife

SutroVax Inc.

Sanofi Pasteur SA.

Pfizer

Sinovac Biotech Ltd.

IDT Biologics GmbH

GreenSignal Bio Pharma Limited

Taj Pharmaceuticals Limited

Bavarian Nordic(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Conjugate Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Conjugate Vaccines Market. The Conjugate Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East &

Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for

navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. The increasing FDA approvals for conjugate vaccines are expected to drive market growth.

4.1.2. Restraints:

4.1.2.1. Fewer side effects of the conjugate vaccine are expected to hamper the market growth.

4.1.3. Opportunity

4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces

5.2. Supply Chain

5.3. Pricing Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market

6.1.1. Before the COVID-19 Market Scenario

6.1.2. Present COVID-19 Market Scenario

6.1.3. After COVID-19 or a Future Scenario

6.2. Pricing Dynamics Amid Covid-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During the Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY PRODUCT TYPE

7.1. Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

7.1.2. Market Attractiveness Index, By Product Type

7.2. Monovalent Conjugate Vaccines*

7.2.1.1. Introduction

7.2.1.2. Market Size Analysis, US\$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030

7.3. Multivalent Conjugate Vaccine

8. BY DISEASE INDICATION

8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

8.1.2. Market Attractiveness Index, By Disease Indication

8.2. Pneumococcal*

8.2.1.1. Introduction

8.2.1.2. Market Size Analysis, US\$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030

8.3. Influenza

8.4. Meningococcal

8.5. Others

9. BY PATHOGEN TYPE

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

9.1.2. Market Attractiveness Index, By Pathogen Type

9.2. Bacterial*

9.2.1.1. Introduction

9.2.1.2. Market Size Analysis, US\$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030

9.3. Viral

10. BY PATIENT TYPE

10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

10.1.2. Market Attractiveness Index, By Patient Type

10.2. Pediatric*

10.2.1.1. Introduction

10.2.1.2. Market Size Analysis, US\$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030

10.3. Adults

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis, US\$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. The U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. The U.K.

11.3.7.3. France

11.3.7.4. Italy

11.3.7.5. Spain

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. Australia

11.5.7.5. Rest of Asia Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication

11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type

11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario

12.2. Market Positioning/Share Analysis

12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. GlaxoSmithKline plc.*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Key Highlights
 - 13.1.4. Financial Overview
- 13.2. Merck & Co. Inc.
- 13.3. Fable
- 13.4. SutroVax Inc.
- 13.5. Sanofi Pasteur SA.
- 13.6. Pfizer
- 13.7. Sinovac Biotech Ltd.
- 13.8. IDT Biologics GmbH
- 13.9. GreenSignal Bio Pharma Limited
- 13.10. Taj Pharmaceuticals Limited
- 13.11. Bavarian Nordic(*LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

- 14.1. Appendix
- 14.2. About Us
- 14.3. Contact Us

I would like to order

Product name: Conjugate Vaccines Market 2026

Product link: <https://marketpublishers.com/r/C93932A0DE91EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C93932A0DE91EN.html>